+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Use of Cardiac Troponin T, Creatine Kinase and Its Isof orm to Monitor Myocardial Injury during Radiofrequency Ablation for Supraventricular Tachycardia

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          To determine whether radiofrequency ablation for supraventricular tachycardia causes significant minor myocardial injury, 16 patients with supraventricular tachycardia undergoing radiofrequency ablation were studied. Cardiac troponin T, creatine kinase and its MB form (CKMB) were measured before, immediately after ablation and every 6 h thereafter for 24 h to detect myocardial injury. Elevation of creatine kinase, CKMB and cardiac troponin T was observed in 6, 4 and 5 patients, respectively. The peak mean creatine kinase concentration was 167 ± 152 IU/1 and that of CKMB was 9 ± 6 IU/1. The peak mean cardiac troponin T level was 0.44 ± 0.47 ng/ml. The frequency of elevated measurements was not statistically different among creatine kinase, CKMB and cardiac troponin T. The mean pulse numbers of ablation, mean duration of ablation, radiofrequency current and mean total energy did not differ statistically between those with or without elevated cardiac troponin T. It was concluded that radiofrequency ablation for supraventricular tachycardia indeed caused some minor myocardial injury and the frequency of elevated cardiac troponin T was comparable to that of CKMB.

          Related collections

          Author and article information

          S. Karger AG
          19 November 2008
          : 87
          : 5
          : 392-395
          aDepartment of Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital, and bDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
          177126 Cardiology 1996;87:392–395
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Arrhythmias, Electrophysiology and Electrocardiography


          Comment on this article